The organizations will assess the efficacy of various treatment combinations using three of Pfizer’s investigational immunotherapies, among other drugs, through six different clinical trials.
An MD Anderson-Pfizer joint steering committee will oversee the trials, most of which will launch in late 2017.
“This alliance aims to define patients with solid tumors who may benefit from immunotherapy and to develop therapy resistance strategies,” said Aung Naing, MD, associate professor of investigational cancer therapeutics at MD Anderson. “Our comprehensive approach will allow us to study new combinations of immunotherapy and standard therapies for patients with solid tumors in need of new treatment options.”
More articles on supply chain:
How this movie studio is challenging blood draw restrictions
Why pharmaceutical products in the US don’t include braille labeling
Abbott earns FDA approval for MRI-compatible defibrillator
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.